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Prevention of T-Cell Activation by rhCTLA4-lg and Anti-CD40L 
Monoclonal Antibody Results in Indefinite Islet Allograft Survival 
C. Rasteilini, A. Salam, R. Kuddus, A. Aitouche, v. Subbotin, M. Braun, R. Leach, R. Peach, J.J. Fung, 
T.E. Starzl, and A.S. Rao 
BLOCKADE of CD28/B7 and/or CD40/CD40L path-
ways has been employed with reasonable success to 
prevent organ allograft rejection.1.:! Additionally, contem-
poraneous but not discrete use of rhCfLA4-Ig and anti-
CD40L monoclonal antibody (MAb) has also been shown 
to prevent chronic rejection.1.3 In the realm of cellular 
transplantation (Tx), it has been reported that the use of 
either rhCfLA4-Ig or anti-CD40L MAb alone resulted in 
prolongation but not indefinite survival of islet allografts.4 ,5 
Based on these observations, we hypothesized that com-
bined transient perioperative blockade of both costimula-
tory pathways would result in indefinite islet allograft 
survival, thus allowing maintenance of euglycemia in a 
diabetic recipient without the need for exogenous insulin. 
This latter tenet was tested in an MHC-incompatible mouse 
model of islet cell Tx; the outcome of this novel study is 
presented herein. 
MATERIALS AND METHODS 
Animals and Islet Cell Tx 
Inbred male DBN2 (H_2d ) and C3H (H-2k) mice were used as 
donors and recipients. respectively. On day 4. the recipients were 
rendered diabetic by a single injection of streptozocin (STZ; 300 
mg/kg; IV). Animals with documented hyperglycemia received 
donor islets (-600) under the left kidney capsule and their blood 
glucose level was sequentially monitored thereafter. In selected 
long-term survivors. intraperitoneal glucose tolerance test 
(IPGTT) was also performed. In all recipients exhibiting indefinite 
islet allograft survival, the graft-bearing kidney was ultimately 
removed. Depending on the treatment protocol, the animals were 
divided into five groups (Table I). 
RESULTS AND DISCUSSION 
In an untreated MHC-incompatible mouse strain combina-
tion, islet allografts were rejected within 19 days' post-Tx 
(Table I; Group I). Comparable survival was also witnessed 
when recipients were treated with isotype-matched control 
antibodies (Table I; Group II). In contrast. treatment with 
anti-CD .. WL MAb resulted in accelerated rejection of the 
graft with recurrence of hyperglycemia by day 13 post-Tx 
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Table 1. Islet Allograft Survival in DBAl2-+C3H Recipients 
Treated With rhCTLA4-lg and/or anti-C040 MAb 
Groups n Treatment Graft Survival (eI) 
4 None 12,13,16,19 
II 4 Human 17, 20, 23, 24 
IgG + hamster IgG 
III 6 anti-CD40L MAb* 13,13, 13. 13, 13, 13 
IV 7 rhCTLA4-lgt 8, 12, 17, 24, 26, 54, 66 
V~ 9 anti-CD40L MAb* >81(~1, >90(tl, >120Itl, 
rhCTlA4-lgt >180(ti 
'250 ILg/d on days 0, 2. and 4 post-Tx; i.m. 
t200 ILg/d on days O. 2, 4, and 6 post-Tx; i.p. 
iLong-surviving animals were electively sacrificed at various times post-Tx to 
undertake both in vivo and in vitro analyses. 
(Table 1; Group III). Interestingly, 5/7 (71 %) of the recip-
ients receiving rhCfLA4-Ig rejected their grafts within 26 
days' post-Tx (Table 1, Group IV); only 2/7 (29%) recipi-
ents in the latter group had graft survivals of 54 and 66 days, 
respectively. Nevertheless, despite the latter observation, it 
was evident that discrete blockade of either CD28/B7 or 
CD40/CD40L pathways is not sufficient to prevent islet 
allograft rejection. On the contrary, indefinite islet allograft 
survival was witnessed in recipients treated perioperatively 
with both rhCfLA4-Ig and anti-CD40L MAb (Table 1; 
Group V). Selected recipients (n = 3) from this group when 
subjected to IPGTI at day 50 post-Tx reversed induced 
hyperglycemia within 30 minutes' postg]ucose infusion. 
Additionally, removal of graft-bearing kidneys in these 
long-term survivors was followed by demonstrable elevation 
in blood glucose levels to > 250 ILgldL, suggesting that the 
observed euglycemia was indeed maintained by trans-
planted islets and not by regeneration of the {3 cells in the 
native pancreata. Finally, these encouraging observations 
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have prompted us to suggest that clinical translation of this 
strateb'Y would greatly improve survival of islets allotrans-
planted into insulin-dependent type I uiabetics with long-
term freedom from exogenous insulin. 
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